Comprehensive genetic analysis for identification of monogenic disorders and selection of appropriate treatments in pediatric patients with persistent thrombocytopenia
Daichi Sato Hinako Kirikae Tomohiro Nakano Saori Katayama Hisao Yaoita Jun Takayama Gen Tamiya Shigeo Kure Atsuo Kikuchi Yoji Sasahara a Department of Pediatrics,Tohoku University Graduate School of Medicine,Miyagi,Japanb Department of Rare Disease Genomics,Tohoku University Graduate School of Medicine,Miyagi,Japanc Department of AI and Innovative Medicine,Tohoku University Graduate School of Medicine,Miyagi,Japand Statistical Genetics Team,RIKEN Center for Advanced Intelligence Project,Tokyo,Japane Miyagi Children's Hospital,Miyagi,Japan
DOI: https://doi.org/10.1080/08880018.2024.2395358
2024-09-25
Pediatric Hematology and Oncology
Abstract:Persistent thrombocytopenia is caused by various diseases, including immune thrombocytopenia, inherited thrombocytopenia, and inherited bone marrow failure syndromes. Considering the large number of genes responsible for inherited disorders, comprehensive genetic analysis is required to diagnose monogenic disorders. In this study, we enrolled 53 pediatric patients with persistent thrombocytopenia exhibiting visually small or normal-sized platelets. We performed whole-exome sequencing, including 56 genes responsible for inherited thrombocytopenia, and evaluated clinical parameters according to disease type. Among 53 patients, 12 patients (22.6%) were diagnosed with monogenic disorders. Nine patients had a family history of thrombocytopenia. Pathogenic or novel variants of genes responsible for inherited thrombocytopenia were identified in three and six patients, respectively. The variants in genes for inherited thrombocytopenia with large or giant platelets were unexpectedly identified in six patients. Pathogenic variants in genes for inherited bone marrow failure syndromes with systemic features were identified in three patients with atypical symptoms. Since the definitive diagnostic methods for immune thrombocytopenia are limited, and a substantial number of patients with inherited thrombocytopenia are at a high risk of developing malignancies, comprehensive genetic analysis is indispensable for selecting appropriate therapies, avoidance of unnecessary treatments for immune thrombocytopenia, and long-term follow-up of patients with inherited thrombocytopenia.
oncology,pediatrics,hematology